The prevalence of overweight and obesity has reached pandemic proportions, affecting more than 1 billion people worldwide; it represents a major driver of cardiovascular morbidity, mortality, and ...
Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch ...
The results of a late-stage drug trial released Thursday are raising hopes that type 1 diabetes patients with chronic kidney ...
UNC School of Medicine researchers have led an international clinical trial of patients with generalized myasthenia gravis, ...
A new pancreatic cancer therapy targets sugar molecules on cell surfaces, offering hope where traditional immunotherapies ...
Prevent Blindness, the nation's leading patient advocacy organization dedicated to preventing blindness and preserving sight, ...
The FDA approved the drug for Barth syndrome despite findings by its data reviewers that the treatment, while safe, was no ...
Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to ...
Investing.com -- Biohaven (NYSE:BHVN) stock fell 44% after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the company’s New Drug Application for VYGLXIA ...
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...
Hosted on MSN
Graves' disease is a great risk of recurrence...The Korean Society of Endocrinology announces the la...
Graves' disease is a disease in which thyroid function is excessively elevated due to an autoimmune response. Anti-thyroid ...
In Kentucky, a second wild deer has been confirmed with chronic wasting disease, a fatal neurologic disease that infects deer, elk and moose, but not people, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback